WKN: 905600 ISIN: US69900Q1085 Hallo Leute, da ich eher für die langzeitanlage bin, habe ich einen neuen Thread aufgemacht weil ich der Meinung bin das diese Aktien nicht nur gut zum täglichen traden ist, sondern das man hier längerfristig ein sehr gutes Geld verdienen kann. Auf jeden Fall kommt jetzt zu einer Kapitalerhöhung und die neuen Aktien werden zum Teil weit über den jetzigen Marktpreis liegen! Es könnte sogar passieren das mit 0,10 Dollar neue Aktien gekauft werden!
Diese wichtige Nachricht kam kurz vor dem Börsenschluß in Amerika heraus. Der Börsenkurs hat daraufhin sofort angezogen. 
Ich will hier nicht pushen, aber es könnte durchaus passieren das es in kürze zu einer Kursexplosion kommen könnte! Bei W : O werde ich heute Abend in meinen eigenen Thread weiters darauf eingehen wo ich schon Kurse von 0,10 Dollar in den nächsten 6 Monaten vorausgesagt habe. Ich bin der Meinung das hier was größeres entstehen kann und habe selber gut in diese Aktien eingekauft.
Ich will mich nicht ständig wiederholen, aber an der Berichtsfront zu Paradigm nimmt die Zahl der Repote (Analysen) weiter zu! | Research Reports | Get Research Reports for: | |
| | Released | Contributor | Author | Title | Pages | Price | | 28-Feb-2006 | Reuters Investment Profile | N/A | Paradigm Medical Industries, Inc.: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 11 | $20 | | 27-Feb-2006 | Pechala's Reports | Lubomir Pechala | PARADIGM MEDICAL INDUSTRIES INC (PMED=US) 2-weeks forecast | 1 | $10 | | 27-Feb-2006 | Pechala's Reports | Frantisek Pechala | PARADIGM MEDICAL INDUSTRIES INC (PMED=US) 12-months forecast | 1 | $15 | | 27-Feb-2006 | Wright Reports | N/A | A textual analysis of Paradigm Medical Industries, Inc.'s financial statements, including company description and recent stock performance, versus PharmaNetics, Inc., International Isotopes Inc and Hemosense, Inc.. | 0 | $25 | | 27-Feb-2006 | ValuEngine, Inc. | N/A | ValuEngine Industry Report for HOSPITAL SUPPLIES | 18 | $49 |
|
|
Press Release Source: Paradigm Medical Industries, Inc.
Paradigm Medical Completes $1.5-Million Financing
Wednesday March 1, 3:31 pm ET
SALT LAKE CITY--(BUSINESS WIRE)--March 1, 2006--Paradigm Medical Industries, Inc. (OTCBB: PMED.OB/PMEDW.OB) today announced it has completed the sale of $1.5 million in secured convertible notes, through Laidlaw & Co. (UK) of New York City, and an institutional investor. The notes are to purchased by the investors in three traunches of $500,000 each. Paradigm Medical received the first traunche upon signing definitive investment agreements on February 28, 2006. The Company will receive the second traunche upon the filing of a registration statement with the Securities and Exchange Commission and the third traunche upon the effectiveness of the registration.
ADVERTISEMENT
"Additional capital is needed at this point to provide the Company will adequate funds to expand global sales and marketing programs, especially for the P60 Ultrasound BioMicroscope," said Paradigm Medical's Chief Executive Officer, Raymond P.L. Cannefax. "Moreover, we will now have adequate funds to purchase additional inventory to satisfy expected strong customer demand for all of our products."
The notes are due three years after issuance and are secured by Paradigm Medical's assets, including inventory, accounts payable and intellectual property. The notes are convertible into shares of the Company's common stock at anytime during their term. The conversion price is equal to the lesser of (a) $0.02 per share or (b) the average of the lowest intra-day trading prices during the 20 trading days immediately prior to the conversion date discounted by 40%.
Interest on the notes is payable at 8% per year, payable quarterly in cash, with six-months of interest payable up front. The notes are callable, with prepayment allowed at any time that the price of Paradigm Medical's stock is $0.10 per share or less.
In addition, Paradigm Medical is required to issue warrants to the investors to acquire an aggregate of 12 million shares of the Company's common stock, at an exercise price of $0.10 per share. The warrants will have a five-year term from the date of issuance, with cashless exercise permitted in the event there is not an effective registration statement registering the warrants.
Paradigm Medical is required to register the shares of its common stock issuable upon the conversion of the notes and the exercise of the warrants. The registration statement must be filed with the SEC within 60 days of the February 28, 2006 closing date and the effectiveness of the registration is to be within 135 days of such closing date.
Paradigm Medical Industries, Inc., currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company's corporate offices are located at 2355 South 1070 West, Salt Lake City, Utah 84119. Call (801) 977-8970 or visit us at www.paradigm-medical.com.
This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events or outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.
Contact:
Paradigm Medical Industries, Inc.
Raymond P.L. Cannefax, CEO, 801-977-8970
--------------------------------------------------
Source: Paradigm Medical Industries, Inc. |
Thread abonnieren
